Login / Signup

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.

Manouk K BosS W LamG MottaJ C A HelmijrC M BeaufortE de JongeJ W M MartensE BovenM P H M JansenA JagerS Sleijfer
Published in: Breast cancer research and treatment (2023)
Presence of ESR1 mutations in baseline ctDNA might not be associated with inferior PFS and OS in advanced breast cancer patients treated with paclitaxel/bevacizumab.
Keyphrases
  • estrogen receptor
  • metastatic colorectal cancer
  • chemotherapy induced
  • young adults
  • breast cancer cells
  • circulating tumor cells
  • childhood cancer